EMA: Questions and answers on the review of somatropin-containing medicines

The European Medicines Agency has completed a review of the safety and effectiveness of somatropin-containing medicines. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of somatropin continue to outweigh its risks, but recommended changes to the product information to ensure that somatropin-containing medicines are used appropriately.